The contents of the presentations above are designed for educational and scientific exchange purposes and are not promotional. They may contain information on investigational products or investigational uses of approved products. No conclusions regarding safety and/or efficacy for such investigational products or uses may be made.
This phase 2 study assessed sonrotoclax, an investigational BCL2 inhibitor, in 100 patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (R/R CLL/SLL) in China. The treatment was generally well tolerated, with manageable side effects. The most common (≥30%) treatment-related adverse effects were decreased neutrophil count, decreased platelet count, anemia, hyperuricemia, and decreased white blood cell count. The overall response rate was 76%, and nearly half of the patients achieved deep remission. Responses were seen regardless of genetic risk factors. These findings support further investigation of sonrotoclax in patients with CLL who have received prior BTKi and/or chemoimmunotherapy (intolerance/failure) and have not received prior BCL2 inhibitor.
